









Markets
/
Stocks
/
nasdaq-bysi
/

Beyondspring Inc

BYSI

View Detailed Chart

2.070USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

83.45MMarket Cap

LossP/E TTM



Beyondspring Inc

2.070

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

+0.98%

5 Days

+7.81%

1 Month

-7.17%

6 Months

+22.40%

Year to Date

+26.99%

1 Year

+11.89%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(3)

Buy(5)

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.002

Sell

RSI(14)

46.792

Neutral

STOCH(KDJ)(9,3,3)

70.250

Buy

ATR(14)

0.154

High Vlolatility

CCI(14)

3.934

Neutral

Williams %R

49.123

Neutral

TRIX(12,20)

-0.845

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.016

Buy

MA10

1.957

Buy

MA20

2.106

Sell

MA50

2.207

Sell

MA100

1.879

Buy

MA200

1.845

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Ticker SymbolBYSI

CompanyBeyondspring Inc

CEODr. Lan Huang, Ph.D.

Websitehttps://www.beyondspringpharma.com/en/